The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments,Cancer

当前位置： X-MOL 学术 › Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments
Cancer ( IF 6.1 ) Pub Date : 2021-09-07 , DOI: 10.1002/cncr.33848
Annelot J M Meijer ₁ , Kathy H Li ₂ , Beth Brooks _{3,

4} , Eva Clemens _{1,

5} , Colin J Ross _{6,

7} , Sharad R Rassekh ₈ , Alex E Hoetink ₉ , Martine van Grotel ₁ , Marry M van den Heuvel-Eibrink _{1,

5} , Bruce C Carleton _{2,

6,

10}

Affiliation

Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Department of Audiology and Speech Pathology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
School of Audiology and Speech Science, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.
Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Division of Hematology, Oncology, and Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Utrecht-Wilhelmina Children's Hospital, Utrecht, the Netherlands.
Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clinical characteristics on the course of CIHL.

中文翻译：